Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives

Nicola Antonio Colabufo, Francesco Berardi, Mariangela Cantore, Maria Grazia Perrone, Marialessandra Contino, Carmela Inglese, Mauro Niso, Roberto Perrone, Amalia Azzariti, Grazia Maria Simone, Letizia Porcelli, Angelo Paradiso

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The development of small molecules as P-gp modulating agents and SAR studies on these ligands represented the aim of the present work. A series of 6,7-dimethoxytetrahydroisoquinoline derivatives was prepared and their ability to inhibit P-gp activity has been evaluated. The basic nucleus of these compounds, common to the best P-gp inhibitors such as Tariquidar and Elacridar, has been functionalized with no-basic moiety from our studied sigma receptor ligands displaying potent P-gp inhibition. The best results were obtained for compounds 3c and 3a (EC50 = 1.64 and 4.86 μM, respectively) and these results were remarkable because Elacridar showed in the same biological evaluation similar inhibitory activity (EC50 = 2 μM). SAR studies displayed that the removal of double bond on the spacer or its shifting into tetraline ring decreased the P-gp inhibiting activity. Moreover, the P-gp inhibition mechanism of tested compounds was investigated by three selected biological experiments. The results displayed that only compound 3c was P-gp inhibitor as Elacridar, while compound 3a and reference compounds Cyclosporin A and Verapamil modulated P-gp activity saturating the efflux pump as substrates. Flow cytometry studies carried out in Doxorubicin resistant breast cancer cell line (MCF7/Adr) confirmed that compound 3c increased Doxorubicin cell accumulation 5.7-fold. In addition, in MCF7/Adr, antiproliferative effect of 5 μM Doxorubicin shifted from 5% to 95% when co-administered with compound 3c (20 μM). The present study suggested a new class of small molecules displaying P-gp inhibitor activity differing from reference compounds Elacridar and Tariquidar for a simplified, and in the meantime, efficacious no-basic moiety.

Original languageEnglish
Pages (from-to)362-373
Number of pages12
JournalBioorganic and Medicinal Chemistry
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 1 2008

Fingerprint

Tetrahydroisoquinolines
Doxorubicin
Derivatives
Molecules
sigma Receptors
Ligands
Flow cytometry
Verapamil
Cyclosporine
Flow Cytometry
Cells
Pumps
Breast Neoplasms
Cell Line
Elacridar
Substrates
Experiments
tariquidar

Keywords

  • Caco-2 cells
  • MCF-7/Adr cells
  • P-Glycoprotein
  • P-gp inhibitors
  • Tetrahydroisoquinoline derivatives
  • Vinblastine transport

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Small P-gp modulating molecules : SAR studies on tetrahydroisoquinoline derivatives. / Colabufo, Nicola Antonio; Berardi, Francesco; Cantore, Mariangela; Perrone, Maria Grazia; Contino, Marialessandra; Inglese, Carmela; Niso, Mauro; Perrone, Roberto; Azzariti, Amalia; Simone, Grazia Maria; Porcelli, Letizia; Paradiso, Angelo.

In: Bioorganic and Medicinal Chemistry, Vol. 16, No. 1, 01.01.2008, p. 362-373.

Research output: Contribution to journalArticle

Colabufo, NA, Berardi, F, Cantore, M, Perrone, MG, Contino, M, Inglese, C, Niso, M, Perrone, R, Azzariti, A, Simone, GM, Porcelli, L & Paradiso, A 2008, 'Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives', Bioorganic and Medicinal Chemistry, vol. 16, no. 1, pp. 362-373. https://doi.org/10.1016/j.bmc.2007.09.039
Colabufo NA, Berardi F, Cantore M, Perrone MG, Contino M, Inglese C et al. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorganic and Medicinal Chemistry. 2008 Jan 1;16(1):362-373. https://doi.org/10.1016/j.bmc.2007.09.039
Colabufo, Nicola Antonio ; Berardi, Francesco ; Cantore, Mariangela ; Perrone, Maria Grazia ; Contino, Marialessandra ; Inglese, Carmela ; Niso, Mauro ; Perrone, Roberto ; Azzariti, Amalia ; Simone, Grazia Maria ; Porcelli, Letizia ; Paradiso, Angelo. / Small P-gp modulating molecules : SAR studies on tetrahydroisoquinoline derivatives. In: Bioorganic and Medicinal Chemistry. 2008 ; Vol. 16, No. 1. pp. 362-373.
@article{22ee6ae0e4d441bf877b4cc42900b5fe,
title = "Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives",
abstract = "The development of small molecules as P-gp modulating agents and SAR studies on these ligands represented the aim of the present work. A series of 6,7-dimethoxytetrahydroisoquinoline derivatives was prepared and their ability to inhibit P-gp activity has been evaluated. The basic nucleus of these compounds, common to the best P-gp inhibitors such as Tariquidar and Elacridar, has been functionalized with no-basic moiety from our studied sigma receptor ligands displaying potent P-gp inhibition. The best results were obtained for compounds 3c and 3a (EC50 = 1.64 and 4.86 μM, respectively) and these results were remarkable because Elacridar showed in the same biological evaluation similar inhibitory activity (EC50 = 2 μM). SAR studies displayed that the removal of double bond on the spacer or its shifting into tetraline ring decreased the P-gp inhibiting activity. Moreover, the P-gp inhibition mechanism of tested compounds was investigated by three selected biological experiments. The results displayed that only compound 3c was P-gp inhibitor as Elacridar, while compound 3a and reference compounds Cyclosporin A and Verapamil modulated P-gp activity saturating the efflux pump as substrates. Flow cytometry studies carried out in Doxorubicin resistant breast cancer cell line (MCF7/Adr) confirmed that compound 3c increased Doxorubicin cell accumulation 5.7-fold. In addition, in MCF7/Adr, antiproliferative effect of 5 μM Doxorubicin shifted from 5{\%} to 95{\%} when co-administered with compound 3c (20 μM). The present study suggested a new class of small molecules displaying P-gp inhibitor activity differing from reference compounds Elacridar and Tariquidar for a simplified, and in the meantime, efficacious no-basic moiety.",
keywords = "Caco-2 cells, MCF-7/Adr cells, P-Glycoprotein, P-gp inhibitors, Tetrahydroisoquinoline derivatives, Vinblastine transport",
author = "Colabufo, {Nicola Antonio} and Francesco Berardi and Mariangela Cantore and Perrone, {Maria Grazia} and Marialessandra Contino and Carmela Inglese and Mauro Niso and Roberto Perrone and Amalia Azzariti and Simone, {Grazia Maria} and Letizia Porcelli and Angelo Paradiso",
year = "2008",
month = "1",
day = "1",
doi = "10.1016/j.bmc.2007.09.039",
language = "English",
volume = "16",
pages = "362--373",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Small P-gp modulating molecules

T2 - SAR studies on tetrahydroisoquinoline derivatives

AU - Colabufo, Nicola Antonio

AU - Berardi, Francesco

AU - Cantore, Mariangela

AU - Perrone, Maria Grazia

AU - Contino, Marialessandra

AU - Inglese, Carmela

AU - Niso, Mauro

AU - Perrone, Roberto

AU - Azzariti, Amalia

AU - Simone, Grazia Maria

AU - Porcelli, Letizia

AU - Paradiso, Angelo

PY - 2008/1/1

Y1 - 2008/1/1

N2 - The development of small molecules as P-gp modulating agents and SAR studies on these ligands represented the aim of the present work. A series of 6,7-dimethoxytetrahydroisoquinoline derivatives was prepared and their ability to inhibit P-gp activity has been evaluated. The basic nucleus of these compounds, common to the best P-gp inhibitors such as Tariquidar and Elacridar, has been functionalized with no-basic moiety from our studied sigma receptor ligands displaying potent P-gp inhibition. The best results were obtained for compounds 3c and 3a (EC50 = 1.64 and 4.86 μM, respectively) and these results were remarkable because Elacridar showed in the same biological evaluation similar inhibitory activity (EC50 = 2 μM). SAR studies displayed that the removal of double bond on the spacer or its shifting into tetraline ring decreased the P-gp inhibiting activity. Moreover, the P-gp inhibition mechanism of tested compounds was investigated by three selected biological experiments. The results displayed that only compound 3c was P-gp inhibitor as Elacridar, while compound 3a and reference compounds Cyclosporin A and Verapamil modulated P-gp activity saturating the efflux pump as substrates. Flow cytometry studies carried out in Doxorubicin resistant breast cancer cell line (MCF7/Adr) confirmed that compound 3c increased Doxorubicin cell accumulation 5.7-fold. In addition, in MCF7/Adr, antiproliferative effect of 5 μM Doxorubicin shifted from 5% to 95% when co-administered with compound 3c (20 μM). The present study suggested a new class of small molecules displaying P-gp inhibitor activity differing from reference compounds Elacridar and Tariquidar for a simplified, and in the meantime, efficacious no-basic moiety.

AB - The development of small molecules as P-gp modulating agents and SAR studies on these ligands represented the aim of the present work. A series of 6,7-dimethoxytetrahydroisoquinoline derivatives was prepared and their ability to inhibit P-gp activity has been evaluated. The basic nucleus of these compounds, common to the best P-gp inhibitors such as Tariquidar and Elacridar, has been functionalized with no-basic moiety from our studied sigma receptor ligands displaying potent P-gp inhibition. The best results were obtained for compounds 3c and 3a (EC50 = 1.64 and 4.86 μM, respectively) and these results were remarkable because Elacridar showed in the same biological evaluation similar inhibitory activity (EC50 = 2 μM). SAR studies displayed that the removal of double bond on the spacer or its shifting into tetraline ring decreased the P-gp inhibiting activity. Moreover, the P-gp inhibition mechanism of tested compounds was investigated by three selected biological experiments. The results displayed that only compound 3c was P-gp inhibitor as Elacridar, while compound 3a and reference compounds Cyclosporin A and Verapamil modulated P-gp activity saturating the efflux pump as substrates. Flow cytometry studies carried out in Doxorubicin resistant breast cancer cell line (MCF7/Adr) confirmed that compound 3c increased Doxorubicin cell accumulation 5.7-fold. In addition, in MCF7/Adr, antiproliferative effect of 5 μM Doxorubicin shifted from 5% to 95% when co-administered with compound 3c (20 μM). The present study suggested a new class of small molecules displaying P-gp inhibitor activity differing from reference compounds Elacridar and Tariquidar for a simplified, and in the meantime, efficacious no-basic moiety.

KW - Caco-2 cells

KW - MCF-7/Adr cells

KW - P-Glycoprotein

KW - P-gp inhibitors

KW - Tetrahydroisoquinoline derivatives

KW - Vinblastine transport

UR - http://www.scopus.com/inward/record.url?scp=38049030187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049030187&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2007.09.039

DO - 10.1016/j.bmc.2007.09.039

M3 - Article

C2 - 17936633

AN - SCOPUS:38049030187

VL - 16

SP - 362

EP - 373

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 1

ER -